Accelerate Pharmaceutical Drug Discovery and Clinical Trials


Drug development, from initial discovery of a promising target to the final medication, is an expensive, lengthy, and incremental process. With trials that can take upwards of over 10 years to complete, reducing the time and cost of the R&D process as a whole, and of clinical trials in particular, is of utmost importance.

The more money companies must invest, the more risk there is of losing investment, and the longer this process drags on, the more likely the company will lose its competitive advantage. So what can be done to accelerate pharmaceutical drug discovery and clinical trials? 


The Total Brain Solution

Total Brain offers a unique solution for accelerating the research of pharmaceutical companies pursuing precision drug discovery and clinical trials, drawing on the world’s largest international neuroscientific database, as well as our International Study to Predict Optimized Treatment for Depression (iSPOT-D). Complementing this dataset is Total Brain’s iSPOT-D data, the largest study of its kind in depression which has been published in 55 peer-reviewed publications. The study has identified objective indicators of treatment response in more than 1,700 depressed individuals using a range of clinical measures. These datasets can be licensed in whole, or in part, to support your companies’ clinical studies and precision drug development efforts.

Data and Software Licensing

Combining Total Brain’s international neuroscientific database, comprised of more than 1.3M standardized datasets, along with our robust mental health monitoring and support platform, provides pharmaceutical companies a way to more easily monitor and track patient progress during clinical trials.

These datasets can be licensed in whole, or in part, to support your companies’ clinical studies and precision drug development efforts.


The Total Brain Advantage

Total Brain’s clinically validated, digital assessment enables monitoring of cognitive and emotional functioning via 12 brain capacities, with integrated clinical screenings for 7 mental conditions like Addiction (CAGE-AID), Depression (PHQ-9), Anxiety (GAD7) and PTSD (PC-PTSD-5), among others.


Monitor Patient Progress

The assessment is designed to be repeated monthly, with results feeding a clinician dashboard to provide ongoing, objective patient data during clinical trials. Total Brain’s clinical support dashboard:

  • Monitors risk and capacity trends for patients
  • Flags for newly identified risk or changes from previous assessment
  • Visualizes patient progress over time
  • Helps assess overall outcomes via aggregate patient analytics

Ready to get started?

Schedule a meeting with a member of our team to learn how Total Brain can help you accelerate pharmaceutical drug discovery and clinical trials.